| sertraline / Generic mfg. |
| Completed | 3 | 20 | US | sertraline, venlafaxine XR | Vanderbilt University, Pfizer | Major Depressive Disorder | | 04/03 | | |
NCT00179257: The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram |
|
|
| Completed | 3 | 20 | US | sertraline (Zoloft) | Vanderbilt University, Pfizer | Major Depressive Disorder | | 03/05 | | |
NCT02122393: A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression |
|
|
| Completed | 3 | 45 | RoW | Sertraline, Cognitive Behavioural Therapy | University of Melbourne, Pfizer | Depression, Anxiety | 04/05 | 04/05 | | |
NCT00232167: Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression |
|
|
| Terminated | 3 | 380 | US | Indiplon, Sertraline | Neurocrine Biosciences | Insomnia, Depression | | 04/06 | | |
| Completed | 3 | 494 | Canada, Europe, RoW | Quetiapine, Amitriptyline, Bupropion, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine | AstraZeneca | Major Depressive Disorder | | 04/07 | | |
NCT00174590: Treatment of Major Depressive Disorder With Psychotic Features. |
|
|
| Terminated | 3 | 30 | US | risperidone | Rush University Medical Center, Janssen, LP | Major Depression With Psychotic Features | | 08/07 | | |
| Completed | 3 | 27 | Europe | Extended release quetiapine (quetiapine XR), SEROQUEL XR®, Sertraline, Zoloft, adequate mood stabilizer | AstraZeneca | Bipolar Disorder, Bipolar Depression | 02/11 | 02/11 | | |
| Completed | 3 | 101 | US | Supervised Aerobic Exercise, Sertraline, Placebo Pill. | Duke University, Pfizer | Depression, Heart Diseases | 07/11 | 12/11 | | |
NCT01987960 / 2012-004982-41: Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD) |
|
|
| Terminated | 3 | 417 | US, Europe, RoW | Placebo, Brexpiprazole | H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. | Post-traumatic Stress Disorder, PTSD | 10/15 | 10/15 | | |
| Completed | 3 | 2944 | Canada, US, Europe, RoW | OPC-34712, Escitalopram, Lexapro, Fluoxetine, Prozac, Paroxetine CR, Paxil CR, Sertraline, Zoloft, Duloxetine, Cymbalta, Venlafaxine XR, Effexor XR | Otsuka Pharmaceutical Development & Commercialization, Inc. | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | 04/17 | 05/17 | | |
|
TRANSFORM-2, NCT02418585 / 2014-004585-22: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 236 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 06/17 | 11/17 | | |
|
TRANSFORM-3, NCT02422186 / 2014-004588-19: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 139 | Europe, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 08/17 | 08/17 | | |
|
| Completed | 3 | 802 | Europe, US, RoW | Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 10/17 | 10/17 | | |
| Completed | 3 | 719 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 02/18 | 02/18 | | |
TRANSFORM-1, NCT02417064 / 2014-004584-20: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 346 | Europe, Canada, US, RoW | Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Treatment-resistant Depression | 02/18 | 02/18 | | |
|
2020-002787-32: Antidepressant for the prevention of DEPression following first episode Psychosis trial |
|
|
| Not yet recruiting | 3 | 508 | Europe | Sertraline, Film-coated tablet | University of Birmingham, National Institute for Health Research | Patients with First Episode Psychosis., Patients who are experience symptoms of psychosis for the first time., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT03434041: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression |
|
|
| Completed | 3 | 252 | US, RoW | Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant) | Janssen Research & Development, LLC | Depressive Disorder, Treatment-Resistant | 04/21 | 04/21 | | |
NCT03852160: A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression |
|
|
| Withdrawn | 3 | 0 | NA | Esketamine 28 mg, JNJ-54135419, Esketamine 56 mg, Esketamine 84 mg, Placebo, Escitalopram, Sertraline, Duloxetine, Mirtazapine, Agomelatine, Bupropion, Trazodone Prolonged Release | Janssen-Cilag International NV | Depressive Disorder, Treatment-Resistant | 07/21 | 07/21 | | |
NCT04476030: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 440 | US | SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine | Biogen | Depressive Disorder, Major | 10/21 | 12/21 | | |
|
|
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 1149 | US | Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 07/22 | 07/22 | | |
NCT04124614: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD |
|
|
| Completed | 3 | 450 | US | Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Post Traumatic Stress Disorder | 07/23 | 08/23 | | |
NCT04174170: Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder |
|
|
| Completed | 3 | 591 | US | Brexpiprazole, Rexulti, Sertraline, Zoloft, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Post Traumatic Stress Disorder | 07/23 | 08/23 | | |
NCT00340379: Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression |
|
|
| Completed | 2/3 | 72 | US, RoW | Ziprasidone, Geodon, Sertraline, Zoloft, Haloperidol, Haldol | Duke University, Pfizer, National Institute of Mental Health and Neuro Sciences, India | Affective Disorders | 08/05 | 08/05 | | |
| Completed | 2/3 | 80 | US | sertraline and risperidone | Duke University, Janssen Pharmaceuticals | Post-Traumatic Stress Disorder | | 07/06 | | |
